0
Please log in or register to do it.

Professor Kwon Sun-eok, Department of Neurology, Asan Medical Center, Seoul, giving a presentation

Professor Kwon Sun-eok, Department of Neurology, Asan Medical Center, Seoul, giving a presentation

(Seoul = Larose.VIP) Reporter Kim Hyun-soo = GNT Pharma, a new drug development company, announced on the 13th that it has confirmed the efficacy of the stroke treatment drug ‘Nelonemdaz’ under development in phase 3 clinical trials.

GNT Pharma reported that the research results were announced by Professor Soon-Eok Kwon of the Department of Neurology at Asan Medical Center in Seoul at the International Stroke Conference (ISC 2024) held at the Phoenix Convention Center in Arizona, USA on the 8th (local time).

This phase 3 clinical trial was conducted on 496 patients who received the drug within 7 hours of arriving at the emergency room after suffering a severe stroke and underwent intra-arterial thrombectomy within 12 hours.

As a result of analyzing the disability improvement effect and safety of the treatment after 12 weeks, GNT Pharma explained that the disability improvement treatment effect in the patient group administered nelonemdaz within 1 hour of arriving at the emergency room was 4.93 times higher than the placebo group.

The 40 patients who received nelonemdaz within 70 minutes of arriving at the emergency room also had a significantly higher disability improvement effect than the 39 patients who received placebo.

The company explained that the distribution and ratio of the modified Rankine Scale (mRS), which evaluates disability in stroke patients, showed no difference between the nelonemdaz and placebo groups, confirming the safety of nelonemdaz.

According to GNT Pharma, Nelonemdaz is a dual-target brain cell protection drug developed with support from the Ministry of Science and ICT and Gyeonggi Province.

It inhibits NMDA glutamate receptors, which can cause brain nerve cell death, and removes free radicals, which are harmful substances, to block excitatory neurotoxicity and free radical toxicity, which are the causes of brain cell death after stroke.

Byeong-joo Kwak, CEO of GNT Pharma, said, “The effect of Nelonemdaz on improving cranial nerve dysfunction was confirmed in patients whose blocked blood vessels were reopened within the golden time after cardiac arrest and stroke,” adding, “With the goal of entering the global market, we are providing rapid thrombectomy after arrival in the emergency room.” “We will conduct an additional multinational phase 3 clinical trial to confirm whether the patient’s disability improves with the implementation and administration of nelonemdaz,” he said.

hyunsu@yna.co.kr

Report to KakaoTalk okjebo 2024/02/13 17:06 Sent

Hanmi Pharmaceutical Group, intensifying conflict over management rights... Preview of general shareholders' vote (comprehensive)
Public health care institutions prepare emergency treatment measures... Preparing for collective action by doctors

Reactions

0
0
0
0
0
0
Already reacted for this post.

Reactions

Your email address will not be published. Required fields are marked *